clinical trial · NCT06911502
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Celgene·phase3·recruiting·n = 400
Follicular LymphomaGolcadomideRituximabLenalidomideCyclophosphamideDoxorubicinVincristinePrednisone/PrednisoloneBendamustine
brief summary
The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.
started
Jul 28, 2025
primary completion
Apr 24, 2028
completion
Jul 31, 2030
last updated
Dec 5, 2025
official title
A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) Vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol